This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2032

Conditions

Parkinson Disease

Interventions

BIOLOGICAL

Human Dopaminergic Progenitor Cells

Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain

Trial Locations (1)

Cornell University Weill Medical College, New York

All Listed Sponsors

lead

iRegene Therapeutics Co., Ltd.

INDUSTRY